Ephraim P Hochberg
Overview
Explore the profile of Ephraim P Hochberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
2191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaulen L, Karschnia P, Doubrovinskaia S, Abramson J, Martinez-Lage M, Shankar G, et al.
Am J Hematol
. 2024 Oct;
99(12):2411-2415.
PMID: 39440883
Lymphomatous infiltration of the peripheral nervous system (PNS), termed neurolymphomatosis, represents a distinct extranodal non-Hodgkin lymphoma variant with dismal outcome. CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy has emerged as...
2.
Nemec R, Scherrer-Crosbie M, Abramson J, Redd R, Gilman H, Ho T, et al.
Leuk Lymphoma
. 2024 Feb;
65(6):783-788.
PMID: 38380861
STOP-CA was a multicenter, double-blind, randomized, placebo-controlled trial comparing atorvastatin to placebo in treatment-naïve lymphoma patients receiving anthracycline-based chemotherapy. We performed a preplanned subgroup to analyze the impact of atorvastatin...
3.
Ahn I, Brander D, Ren Y, Zhou Y, Tyekucheva S, Walker H, et al.
Blood Adv
. 2024 Jan;
8(4):832-841.
PMID: 38163317
We previously reported high rates of undetectable minimal residual disease <10-4 (uMRD4) with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) followed by 2-year ibrutinib maintenance (I-M) in treatment-naïve chronic lymphocytic...
4.
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial
Neilan T, Quinaglia T, Onoue T, Mahmood S, Drobni Z, Gilman H, et al.
JAMA
. 2023 Aug;
330(6):528-536.
PMID: 37552303
Importance: Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use of atorvastatin may be associated with a reduction in cardiac dysfunction due to...
5.
Karschnia P, Arrillaga-Romany I, Eichler A, Forst D, Gerstner E, Jordan J, et al.
Neuro Oncol
. 2023 Jul;
25(12):2239-2249.
PMID: 37402650
Background: Chimeric antigen receptor (CAR) T-cells targeting CD19 have been established as a leading engineered T-cell therapy for B-cell lymphomas; however, data for patients with central nervous system (CNS) involvement...
6.
Dias-Santagata D, Heist R, Bard A, da Silva A, Dagogo-Jack I, Nardi V, et al.
Oncologist
. 2022 Jul;
27(11):930-939.
PMID: 35852437
Background: Precision oncology relies on molecular diagnostics, and the value-proposition of modern healthcare networks promises a higher standard of care across partner sites. We present the results of a clinical...
7.
Hoppe R, Advani R, Ai W, Ambinder R, Armand P, Bello C, et al.
J Natl Compr Canc Netw
. 2022 Apr;
20(4):322-334.
PMID: 35390768
Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have...
8.
Haydu J, Maron J, Redd R, Gallagher K, Fischinger S, Barnes J, et al.
Blood Adv
. 2022 Jan;
6(6):1671-1683.
PMID: 35073571
Chronic lymphocytic leukemia (CLL), the most common leukemia worldwide, is associated with increased COVID-19 mortality. Previous studies suggest only a portion of vaccinated CLL patients develop severe acute respiratory syndrome...
9.
Zubiri L, Rosovsky R, Mooradian M, Piper-Vallillo A, Gainor J, Sullivan R, et al.
Oncologist
. 2021 May;
26(8):e1427-e1433.
PMID: 33932247
Background: The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted health care systems. However, to date, the trend of hospitalizations in the oncology patient population has not been studied, and...
10.
Phadke N, Luk S, Hochberg E, Banerji A
J Oncol Pharm Pract
. 2021 Apr;
27(7):1802-1805.
PMID: 33793357
Introduction: Although up to half of patients receiving chemotherapeutic agents develop hypersensitivity reactions to the same, desensitization protocols can induce temporary tolerance to allow patients to continue to receive first-line...